Syros says on track to report data on SY-1425 combinations, SY-1365
In a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 10:30 a.m. PST, the company will detail its three strategic priorities for the year: Aggressively advancing its two clinical-stage programs with planned data readouts on two combinations with SY-1425, a first-in-class selective retinoic acid receptor alpha agonist, from the ongoing Phase 2 trial in genomically defined acute myeloid leukemia and myelodysplastic syndrome patients, and with the first clinical data for SY-1365, a first-in-class selective cyclin-dependent kinase 7 inhibitor, from the Phase 1 trial in advanced solid tumors. Leveraging its leading gene control platform to fuel its discovery and preclinical pipeline in oncology, including immuno-oncology, and the recent expansion into monogenic diseases, keeping the Company on track to achieve its goal of delivering one Investigational New Drug application every other year on average. Building on its strong fundamentals to continue its evolution toward a fully integrated biopharmaceutical company with therapies that transform patients' lives. Based on its current operating plans, Syros expects that its existing cash, cash equivalents and marketable securities, together with the upfront cash and equity investment from its collaboration with Incyte, will enable the Company to fund its anticipated operating expenses and capital expenditure requirements into 2019. Syros had approximately $81.9 million in cash, cash equivalents and marketable securities as of September 30, 2017.